Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.
about
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsTiming and extent of response in colorectal cancer: critical review of current data and implication for future trialsAnti-angiogenic agents in metastatic colorectal cancerTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyCurrent position of ALPPS in the surgical landscape of CRLM treatment proposals.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.A proposed new method for assessing the pathological response to chemotherapy in resected colorectal liver metastases.Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to Y90-radioembolization.Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.BEV-IP: Perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis.Lymphatic Invasion is an Independent Adverse Prognostic Factor in Patients with Colorectal Liver Metastasis.Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic CancerEvidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.Advances in understanding of colorectal liver metastasis and implications for the clinic.Challenges in the multidisciplinary management of stage IV colon and rectal cancer.A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal CancerPrognostic impact of margin status in liver resections for colorectal metastases after bevacizumab.Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.Pathological complete response after neoadjuvant chemotherapy for rectal cancer with synchronous multiple liver metastases: a report of an unusual case.Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'.Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.Tumor histopathology predicts outcomes after resection of colorectal cancer liver metastases treated with and without pre-operative chemotherapy.Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of CompleDNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells.
P2860
Q26773795-B70D90DB-9CA4-4011-81C8-9B88B5D8DA10Q26797292-E3256301-A894-4C07-B5BD-14A797A5F17EQ26801911-D0A20ED7-7DB0-41EC-AC63-42F73F5DBE9FQ26993238-B1119F88-CDCC-4337-8751-BB25736885D5Q27690340-F6EDA3BB-9145-4C5E-BEB1-80B9D9EAC75DQ33770680-9240E565-CEEF-4C44-9FAC-B20D7993FF3FQ33994298-D064B5CE-E7A3-4C6C-8514-4492D7A4A8E7Q35570801-09C6F2C6-92D3-4B4F-A3F9-BD61EF7575EDQ35817933-6A20B8E9-98C3-496F-8A84-12AA424F8610Q35870363-67153C03-6E57-4DD7-AA6E-4C7E5699F958Q36391787-0CB71191-491A-4544-89B2-F15011D769FCQ36852611-9D2796CF-2361-4C12-9620-94DEFC585844Q37408810-167223A0-460A-49B3-AAD8-E7005F48F93AQ38230654-5175738F-F962-47FD-8E9D-A6BB861A8413Q38246361-1DBB3A0B-DE01-46D7-A352-C770A645E324Q38674714-F7DB04C3-2DE0-4547-8A9A-5F69D37EAA51Q38925427-678FEC16-B4A3-49A4-8940-F059AA5D537EQ39038772-4C6D8ED0-4AFC-44BA-BC4C-3EC481B2D897Q41234320-769112EA-318A-4941-8707-3689931941C2Q42814001-07A93C2A-7E5E-4E30-9813-BC3BD3290BD7Q43114077-A2121FDA-8FE8-453C-9E66-2248DDEF3A81Q45032127-640766A3-9693-4C6E-AD5D-26702DCE9437Q49737539-7CEE4DA7-5280-47E9-A3A0-77E5F705129CQ53179257-6FD0B9F4-B651-4770-91DC-A34D8A8CDDA4Q53779084-138AD2A8-8DD2-4A42-85FD-A2A733BF3E69Q55223036-E0EB2512-5DD3-4C8A-8CAB-7C0A1BC77CAE
P2860
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Histopathologic evaluation of ...... th FOLFOXIRI plus bevacizumab.
@en
type
label
Histopathologic evaluation of ...... th FOLFOXIRI plus bevacizumab.
@en
prefLabel
Histopathologic evaluation of ...... th FOLFOXIRI plus bevacizumab.
@en
P2093
P2860
P50
P356
P1476
Histopathologic evaluation of ...... ith FOLFOXIRI plus bevacizumab
@en
P2093
C Antoniotti
C Caparello
C Cremolini
F Marmorino
M Morvillo
P2860
P2888
P304
P356
10.1038/BJC.2013.245
P407
P577
2013-05-23T00:00:00Z